GMAB Maintained by Guggenheim -- Price Target Raised to $54.00

gurufocus.com · 2026-10-05

Genmab (GMAB) Analyst Rating Update - October 5, 2026 On October 5, 2026, Genmab (GMAB) received an updated 'Buy' rating from Guggenheim, with a new price ta

TickrTrends take: Guggenheim's maintenance of coverage alongside a price target raise to $54 suggests analyst confidence in GMAB's fundamentals within the Healthcare sector, aligning with TickrTrends' fairly valued assessment. Investors focused on valuation metrics should monitor whether GMAB's operational performance and financial trajectory can support movement toward or away from this elevated price target, as significant gaps between current pricing and analyst targets often signal either market inefficiency or changing risk factors.

Read the full story at gurufocus.com →